This site is intended for Healthcare Professionals.

Menu

Close

HomeShelf Life & StorageDosing & Administration12 years of age and older5 through 11 years of ageSafety & EfficacyResources

Pfizer-BioNTech COVID-19 Vaccine Authorised for Emergency Use: 
​​​​​​​Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorised by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older. The emergency uses are only authorised for the duration of the declaration that circumstances exist justifying the authorisation of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorisation revoked sooner.
​​​​​​​
​​​​​​​

12 years of age and older
Dosing & Administration
Shelf Life & Storage
5 through 11 years of age
Dosing & Administration
Shelf Life & Storage
Vaccine Formulations GuideChildren ages 5 through 11 years old should only be vaccinated with the 5 through 11 years of age Dilute Before Use Orange Cap presentation. No other vaccine presentation should be used for children 5 through 11 years old because of the potential for vaccine administration errors, including dosing errors. For children who will turn 12 between their first and second dose, consult the EUA Fact Sheets for Vaccination Providers.

The 2 formulations of Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older, when prepared according to their respective instructions for use, can be used interchangeably.

Refer to the information outlined below to understand the differences across age groups and formulations

Formulation

12 years of age and older
​​​​​​​ Dilute Before Use

12 years of age and older
​​​​​​​Do Not Dilute

5 through 11 years of age
​​​​​​​Dilute Before Use

Vial

Multi-dose Vial

Multi-dose Vial

Multi-dose Vial

Vial Cap Color

Purple

Gray

Orange

EUA Fact Sheet for Vaccination Providers

EUA Fact Sheet for Vaccination Providers
[countries to program the hyperlink based on website URL]

EUA Fact Sheet for Vaccination Providers
[countries to program the hyperlink based on website URL]

EUA Fact Sheet for Vaccination Providers
​​​​​​​[countries to program the hyperlink based on website URL]

Dosage

30 mcg

30 mcg

10 mcg

Injection Volume per Dose

0.3 mL

0.3 mL

0.2 mL

Dilution

Dilution required

NO DILUTION

Dilution required

Amount of Diluent
Needed per Vial*

1.8 mL

NO DILUTION

1.3 mL

Doses per Vial

6 doses per vial
(after dilution)

6 doses per vial

10 doses per vial
(after dilution)

Vial Size

2 mL

2 mL

2 mL

Fill Volume per Vial

0.45 mL

2.25 mL

1.3 mL

Storage Conditions

Ultra-Low-Temperature (ULT) Freezer (-90°C to -60°C)

9 months (shelf life)

9 months (shelf life)

9 months (shelf life)

Freezer Storage Time
(-25°C to -15°C) 

2 weeks

DO NOT STORE

DO NOT STORE

Refrigeration Storage Time
(2°C to 8°C) 

1 month

10 weeks

10 weeks

Room Temperature
​​​​​​​(8°C to 25°C)

2 hours prior to dilution
(including any thaw time)

12 hours prior to first puncture
​​​​​​​(including any thaw time)

12 hours prior to dilution
(including any thaw time)

After First Puncture
​​​​​​​(2°C to 25°C)

Discard after 6 hours

Discard after 12 hours

Discard after 12 hours

Package Size

195 vials

10 vials

10 vials

*Diluent: sterile 0.9% Sodium Chloride Injection, USP. Bacteriostatic saline or other diluents must NOT be used.
†Regardless of storage condition, vaccine should not be used past the 9 month expiry (6 months printed on the vial plus additional 3 months for the expiry dates until February 2022. All vials with an expiry date beyond February 2022 will already reflect the 9-month shelf life).
‡Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.

DOWNLOAD THIS GUIDE
Authorised Use

 The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from FDA to prevent COVID-19 in individuals 5 years of age and older to provide:

  • a 10 mcg modRNA 2-dose primary series to individuals 5 through 11 years of age

  • a 30 mcg modRNA 2-dose primary series to individuals 12 years of age and older

  • a 10 mcg modRNA third primary series dose to individuals 5 through 11 years of age who have been determined to have certain kinds of immunocompromise

  • a 30 mcg modRNA third primary series dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

  • a 30 mcg modRNA single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine

  • a 30 mcg modRNA single booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorised or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorised for a booster dose of the vaccine used for primary vaccination

Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine
  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccine, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm

    • The vaccine is only administered intramuscularly by a healthcare professional

    • The vaccine is not taken orally and is not available in a capsule or tablet form

  • Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and are dispensed in a vial as follows:

    • For 12 years of age and older Dilute Before Use, Purple Cap, two versions of the vial label are in current circulation - with or without a purple border

    • For 12 years of age and older Do Not Dilute, Gray Cap, the vial label includes a gray border

    • For 5 through 11 years of age Dilute Before Use, Orange Cap, the vial label includes an orange border

  • Ensure the safety of the vaccine vials by limiting access to only authorised personnel. The location they are stored in must be secure and locked when not in use. To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through government-authorised vaccination centers – such as doctor’s offices, authorised pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccine can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorised vaccination sites. Individual doses are not for sale

 If you suspect the vaccine you have purchased may be counterfeit, contact us at [INSERT LOCAL COUNTRY INFORMATION] .

For more information ​​​​​​​

If you suspect COMIRNATY COVID-19 mRNA Vaccine (nucleoside modified) you have purchased may be counterfeit, contact Customer Service at 0860 Pfizer (734937)

​​​​​​​Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via https://www.pfizersafetyreporting.com/#/en or [email protected] or call +27 0860 PFIZER (734 937)] and include batch/Lot number if available

Submit medical Inquiry with link to the following MI contact details: https://www.pfizermedicalinformation.co.za/en-za/covid-19-mrna-vaccine-bnt162​​​​​​​

Contact

EUA Fact Sheet Updates

Please be aware that Pfizer-BioNTech COVID-19 Vaccine is now available in three formulations. For additional information on differences across age groups and formulations please see Vaccine Formulations Guide on the home page of this website.


Label Update: Effective 03 Jan 2022

2.3 Vaccination Schedule
A single Pfizer‑BioNTech COVID-19 Vaccine booster dose (0.3 mL) may be administered at least 5 months after completing a primary series of the Pfizer-BioNTech COVID-19 Vaccine to individuals 12 years of age and older. 

A third primary series dose of the Pfizer-BioNTech COVID-19 Vaccine supplied in multiple dose vials with orange caps and labels with orange borders (0.2 mL) at least 28 days following the second dose is authorized for administration to individuals 5 through 11 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

Click below to view:
    •    EUA Fact Sheet for Vaccination Providers
- 12 year of age and older Dilute Before Use, Purple Cap
    •    EUA Fact Sheet for Vaccination Providers - 12 years of age and older Do Not Dilute, Gray Cap
    •    EUA Fact Sheet for Vaccination Providers - 5 through 11 years of age Dilute Before Use, Orange Cap​​​​​​​

For healthcare professionals only